The Latest Regenerative Medicine Articles from Streetwise Reports

Data on New Cell Therapy for LBCL Encouraging, Analyst Says

Research Report
  ()
The biopharma behind the investigational treatment plans to advance it into a potentially pivotal clinical program next year, noted a BTIG report.

HSCT/Gene Therapy Co. Sees Many Positive Catalysts in Q422

Research Report
  ()
Hematopoietic stem cell transplantation (HSCT) and gene therapy firm Magenta Therapeutics Inc. recently announced updates related to two of its leading clinical programs. BTIG LLC advised in a research update that it expects Magenta to release updated clinical data from its MGTA-117 and MGTA-145 programs in Q4/22, which will serve as key catalysts for the company. BTIG stated it is reiterating its "Buy" rating and $6/share price target on Magenta Therapeutics.

Showing Results: 1 to 2 of 2